Forms of pravastatin sodium

Details Forms of pravastatin sodium Forms of pravastatin sodium

2006-02-21

2006-02-21

Zucker, Paul A. (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C560S248000, C560S256000

Reexamination Certificate

active

07001919

ABSTRACT:
New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream.

REFERENCES:
patent: 4319039 (1982-03-01), Albers-Schonberg
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4410629 (1983-10-01), Terahara et al.
patent: 4857522 (1989-08-01), DiPietro et al.
patent: 4857547 (1989-08-01), Hoffman et al.
patent: 5099035 (1992-03-01), Saunders et al.
patent: 5140012 (1992-08-01), McGovern et al.
patent: 5153124 (1992-10-01), Furuya et al.
patent: 5157025 (1992-10-01), Aberg et al.
patent: 5180589 (1993-01-01), Joshi et al.
patent: 5202029 (1993-04-01), Hayatko et al.
patent: 5616595 (1997-04-01), Chu et al.
patent: 5712130 (1998-01-01), Hajko et al.
patent: 5883109 (1999-03-01), Gregg et al.
patent: 5942423 (1999-08-01), Demain et al.
patent: 6444452 (2002-09-01), Keri et al.
patent: 6682913 (2004-01-01), Jekkel et al.
patent: 6695969 (2004-02-01), Grahek et al.
patent: 6696599 (2004-02-01), Jekkel et al.
patent: 6750365 (2004-06-01), Jekkel et al.
patent: 2004/0039225 (2004-02-01), Jekkel et al.
patent: 0 215 665 (1987-03-01), None
patent: 0 605 230 (1994-07-01), None
patent: 0 671 170 (1995-09-01), None
patent: WO 92/16276 (1992-10-01), None
patent: WO 98/37220 (1998-08-01), None
patent: WO 98/45410 (1998-10-01), None
patent: WO 99/10499 (1999-03-01), None
patent: WO 99/42601 (1999-08-01), None
patent: WO 00/17182 (2000-03-01), None
patent: WO 00/46175 (2000-08-01), None
patent: WO 01/03647 (2001-01-01), None
patent: WO 01/10813 (2001-02-01), None
patent: WO 2002/030415 (2002-04-01), None
McMaster, Chem 2O06 Lab Manual, 1997, www.chemistry.mcmaster.ca/˜chem2o6/labmanual/ expt1/exp1b-i.html , pp. 1-9.
Budavari, et al. The Merck Index. 1989. Merck and Co., p., 1222.
T. Koga et al., “Tissue-selective Inhibition of cholesterol synthesis in vivo by prevastatin sodium, 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor”,Biochimics at Biophysics Acts, vol. 1045, No. 1, pp. 115-120, Jun. 28, 1990.
Serajuddin et al. “Relative Lipophillicities, Solubillities, and Structure-Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovestatin, Mavestatin, and Simvastatin”,Journal of Pharmaceutical Sciences, vol. 80, No. 9, pp. 830-834, Sep. 1991.

Affiliated with

Also associated with

Rating

Forms of pravastatin sodium does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Forms of pravastatin sodium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Forms of pravastatin sodium will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3634072